Cingulate Completes Final FDA Study for CTx-1301 ADHD Treatment
On January 7, 2025, Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD). This study, specifically a food effect study, represents a significant milestone in the development of the drug. The study involved the administration of a single 50mg dose of […]
More Stories
Top 10 Six Sigma Tools That Will Grow Your Business in 2026
Every company faces the same problems while running its business: repeated mistakes, hidden waste, and insufficient processes that don’t deliver...
Ukraine Reports Crash of One of Its F-16s, Pilot Safe
By Victoria Friedman The Armed Forces of Ukraine said one of its F-16 fighter jets had crashed, and that the...
US Gas Prices Remain Elevated Amid Ongoing Middle East Tensions US Gas Prices Remain Elevated Amid Ongoing Middle East Tensions
By Naveen Athrappully Gasoline prices in the United States continue to remain high at over $4 per gallon as the...
Spain’s Ceuta Overwhelmed as Nearly 60,000 Illegal Immigrants Cross From Morocco in a Day
By Owen Evans Ceuta was overwhelmed overnight as the Spanish North African exclave faced a fresh wave of nearly 60,000...
Spain’s Mass Illegal Immigration Crisis: What to Know
By Troy Myers Tens of thousands of illegal immigrants crossed from Morocco into Spain in a single day, igniting worldwide...
Weekly Unemployment Claims Remain at Historically Low Levels
By Andrew Moran The number of Americans applying for unemployment benefits remained at historically low levels last week, as layoffs...